Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of ICA-105665 Using the Intradermal Capsaicin and Ultraviolet B (UV-B) Models in Healthy Male Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00962663
First received: August 19, 2009
Last updated: September 27, 2012
Last verified: September 2012

August 19, 2009
September 27, 2012
August 2009
December 2009   (final data collection date for primary outcome measure)
Capsaicin: Visual Analogue Scale, hyperalgesia, allodynia, laser Doppler blood flow. UV-B pain assessments: Heat pain detection threshold, Heat pain tolerance threshold (HPTT), Laser Doppler blood flow (intensity and area), Skin temperature. [ Time Frame: Capsaicin - Time 0, to 2 hours after injection. UV-B Pain: 2 hours post ] [ Designated as safety issue: No ]
Capsaicin: Visual Analogue Scale, hyperalgesia, allodynia, laser Doppler blood flow [ Time Frame: Capsaicin - Time 0, to 2 h after injection ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00962663 on ClinicalTrials.gov Archive Site
UV-B: Heat pain,Laser Doppler Blood Flow [ Time Frame: 24 hours after irradiation ] [ Designated as safety issue: No ]
UV-B: Heat pain,Laser Doppler Blood Flow [ Time Frame: 24 h after irradiation ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Effects of ICA-105665 Using the Intradermal Capsaicin and Ultraviolet B (UV-B) Models in Healthy Male Subjects
A Randomized, Placebo-Controlled, 3-way Crossover Study to Investigate the Pharmacodynamic Effects of ICA-105665 Using the Intradermal Capsaicin and UV-B Models in Healthy Male Subjects

The purpose of this study is; to determine the pharmacodynamic (PD) effects of ICA-105665 using the intradermal (ID) capsaicin model in healthy male subjects, and to investigate the effect of ICA-105665 on inflammatory hyperalgesia using the ultraviolet B (UV-B) model in healthy male subjects.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Healthy
  • Drug: ICA-105665
    Subjects randomized to receive ICA -105665 will receive 200 mg BID
  • Drug: Ibuprofen
    Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.
    Other Name: Cuprofen
  • Drug: Placebo

    Subjects randomized to receive placebo will receive placebo to ICA

    -105665 at all scheduled dosing times on Days 1 to 4 and placebo to Ibuprofen on the morning of Day 4.

    Other Name: orange Syrup BP
  • Experimental: ICA-105665
    Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
    Intervention: Drug: ICA-105665
  • Active Comparator: Ibuprofen
    Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
    Intervention: Drug: Ibuprofen
  • Placebo Comparator: Placebo
    Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
December 2009
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy males aged 18 to 55 years (inclusive).
  • Body mass index (BMI) of 18 to 30 kg/m2.
  • Non-smokers and smokers of up to 5 cigarettes or equivalent per day.
  • Must be able to abstain from smoking during residential periods.
  • Demonstration of positive hyperalgesia as defined by an area of hyperalgesia = 15 cm2 15 minutes after ID administration of 100 µg capsaicin.
  • Demonstration of negative hyperalgesia as defined by an area of hyperalgesia < 5 cm2 15 minutes after ID administration of capsaicin vehicle.
  • Subject with a skin type compatible with the measures, and without significant skin allergies, pigmentary disorders, or any active dermatological conditions that might interfere with the conduct of the study.

Exclusion Criteria:

  • Subject has had a clinically significant illness in the 4 weeks before screening.
  • Use of prescribed medications and herbal supplements in the 7 days prior to dosing or over the counter preparations, including multivitamins and paracetamol, in the 48 h before dosing.
  • Subject has a significant history of drug/solvent abuse (within 2 years prior to Day 1), or a positive drugs of abuse test at screening.
  • Subject with a history of alcohol abuse or currently drinks in excess of 28 units per week (males), or has a positive breath alcohol test at the Screening visit or on Day 1.
  • Subject has a Heat pain tolerance threshold (HPTT) of = 50°C at screening.
  • Subjects who do not develop erythema at the highest intensity of UV-B light used to establish Minimum erythema dose (MED).
  • Known allergy or intolerance to capsaicin or hot peppers.
  • Subjects who have any skin trauma, scars or other skin disorder or tattoos on their forearms or on the front of their thighs.
  • Subject with active chronic pain conditions or a history of chronic pain conditions.
  • Any condition that might interfere with the absorption, distribution, metabolism, and/or excretion of drugs.
  • Previous ingestion of ICA-105665.
  • Considering or scheduled to undergo any surgical procedure during the duration of the study.
  • Prolonged QT/QTc interval (repeatedly = 450 msec). Received any agent known to alter hepatic or renal clearance (e.g., erythromycin, cimetidine, barbiturates, phenothiazines, clarithromycin, troleandomycin, ketoconazole, miconazole, fluconazole, itraconazole, etc.) for a period of 30 days prior to Day 1.
  • History of risk factors for Torsades de Pointes (family history of long QT syndrome, heart failure, hypokalemia).
  • Subject is unable to tolerate being blindfolded.
  • Subject has participated in a clinical study involving capsaicin within 1 year of the Screening visit.
  • Subject has a history of skin cancer.
  • Subject has a clinically significant history of anemia.
Male
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00962663
ICA-105665-05, B5311006
No
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP